Oct. 7, 2016…IRVINE, Calif.…Harbor MedTech, Inc., a commercial-stage regenerative medicine company delivering innovative biologic wound healing products, today announced that it has established a medical advisory board comprised of some of the country’s foremost chronic wound care experts. The group will meet at the Symposium on Advanced Wound Care (SAWC) in Las Vegas, Oct. 7-9, 2016.
According to Jerry Mezger, president and CEO of Harbor MedTech, the company formed the advisory board to gain their insights on issues impacting the treatment of chronic wounds and input on the development of advanced wound-healing technologies. The group also serves as an expert resource for clinical research and educational activities related to wound-healing products and care.
In the U.S., more than 3 million chronic skin wounds fail to heal with conventional treatment each year—a problem that is rapidly increasing due to trends in diabetes, circulatory problems, and an aging population. “The use of biologic skin substitutes has become the fastest-growing product segment for chronic wound treatment, but today’s skin substitutes are costly and require many re-applications,” Mezger said. “We are excited to partner with these leading experts to advance Architect®, the first of our unique and novel wound-care technologies, with the goal of improving outcomes for patients suffering from debilitating chronic wounds.”
The Harbor MedTech Medical Advisory Board includes:
• Robert S. Kirsner, M.D., Ph.D., Department of Dermatology, University of Miami
• David Margolis, M.D., Ph.D., Dermatologist, University of Pennsylvania
• William A. Marston, M.D., Vascular Surgeon, UNC School of Medicine, Chapel Hill, N.C.
• John C. Lantis, M.D., Vascular Surgeon, Mount Sinai School of Medicine, New York
• Larry Lavery, DPM, Podiatrist, University of Texas, Southwestern, Dallas
• Paul Kim, DPM, Podiatrist, Georgetown University, Washington, D.C.
About Harbor MedTech
Harbor MedTech, Inc., is a commercial-stage regenerative medicine company that has pioneered a new technology platform for biologic wound healing products. The company’s BriDGE® platform is a major leap forward in tissue regeneration—offering superior performance, proven clinical results, and an excellent economic advantage. Architect®, the company’s first BriDGE-based product, has been shown to heal chronic skin wounds faster than alternative products and generally requires just one application—versus the multiple applications required with other collagen-based skin substitutes. Recent studies demonstrate that it may act by stimulating the patient’s own immune system to accelerate healing. Harbor MedTech was founded in 2010 and is based in Irvine, Calif.
For more information visit www.harbormedtech.com.
Barbara Sullivan, Sullivan & Associates
SAM-0074 rev.A (11/16)